Bristol-Myers Squibb Company (BMY) 68.24 $BMY
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates
at Investor's Business Daily - 53 mins ago
Large-cap drugmakers Valeant Pharmaceuticals, Eli Lilly and Bristol-Myers Squibb all beat analysts' Q2 estimates, but their stocks went in different directions, as their guidance was more mixed. Valeant (VRX) rose more than 6% after it said total...
VRX: 253.84 (+14.92), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Bristol-Myers Squibb Gets a Mixed Message From Investors
Brian Orelli, The Motley Fool - Motley Fool - 58 mins ago
Source: Bristol-Myers Squibb When a company beats revenue expectations by a wide margin, $4.2 billion actual versus a $3.7 billion consensus, as Bristol-Myers Squibb did, you'd expect shares to skyrocket. Instead the pharma is sitting down 1%...
GILD: 117.66 (+0.22), BMY: 68.24 (-1.13)
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:16PM CDT
Merck (MRK) announced that the European Commission has approved KEYTRUDA, for the treatment of advanced (unresectable or metastatic) melanoma in adults.
MRK: 58.07 (-0.06), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Shire Lifts 2015 Guidance On Strong Drug Pipeline
at Investor's Business Daily - Thu Jul 23, 1:42PM CDT
Shire (SHPG) missed analysts' targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker's adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on...
VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.78 (-0.10), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance
at Investor's Business Daily - Thu Jul 23, 9:58AM CDT
Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly's profit, excluding one-time items, rose...
LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Surging new drug sales highlight strong Bristol-Myers Q2
By LINDA A. JOHNSON - AP - Thu Jul 23, 8:40AM CDT
Surging sales for new cancer, heart and hepatitis C medicines helped drugmaker Bristol-Myers Squibb Co. beat Wall Street expectations, and it boosted its 2015 profit forecast.
BMY: 68.24 (-1.13)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Stock Futures Up, But Volatile; SanDisk, Cirrus, Fortinet Soar
at Investor's Business Daily - Thu Jul 23, 8:17AM CDT
Stock futures were off to a neck-wrenching start Thursday, as earnings reports powered a volatile premarket session. Dow futures were up and down, showing a 4-point gain vs. fair market value 45 minutes before the start of regular trade. S&P 500...
AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), AXP: 77.01 (-1.98), RTN: 103.21 (+6.22), BMY: 68.24 (-1.13), QCOM: 61.78 (-2.41), PHM: 20.18 (+0.02), CRUS: 35.72 (+5.01), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), SNDK: 63.70 (+9.52)
Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:48AM CDT
Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View
BMY: 68.24 (-1.13)
Bristol-Myers Squibb Reports Second Quarter Financial Results
Business Wire - Thu Jul 23, 6:30AM CDT
--Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53
BMY: 68.24 (-1.13)
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe
Business Wire - Thu Jul 23, 5:30AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated two of the company's type II variation applications, which seek to extend the current indication for its Immuno-Oncology agent, Opdivo. Validation of the applications confirms that the submissions are complete and starts the EMA's centralized review process.
BMY: 68.24 (-1.13)
Presenting NPS2: Satmetrix to Introduce Next-Gen Net Promoter(R) Methodology at the 2015 International Net Promoter Conference in London, September 10 - 11
Marketwired - Thu Jul 23, 2:01AM CDT
Satmetrix(R), the leading global provider of cloud-based solutions for managing and improving customer experience, is returning to London for its 9th annual International Net Promoter Conference on September 10 - 11, 2015 at Chelsea Football Club's prestigious ground.
BMY: 68.24 (-1.13)
Market Wrap: Down Day Across the Board
at The Street - Wed Jul 22, 3:41PM CDT
Tech, telecom stocks lead major averages lower.
MMM: 149.50 (-5.91), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CZR: 5.14 (+0.38), GM: 31.50 (+1.20), CRUS: 35.72 (+5.01), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), SNDK: 63.70 (+9.52), XOMA: 1.04 (+0.04)
Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:30PM CDT
Bristol-Myers (BMY) announced that the FDA has granted Breakthrough Therapy Designation to HIV candidate, BMS-663068.
SNSS: 3.47 (-0.05), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.43 (unch), CLDX: 25.33 (-0.21), ABBV: 70.52 (-0.04), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Global Kidney Cancer Drugs Market 2015-2019 with Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Pfizer Leading the Market
M2 - Wed Jul 22, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9gbg4/global_kidney) has announced the addition of the "Global Kidney Cancer Drugs Market 2015-2019" report to their offering. The global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019. The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer. The report also includes a discussion of the key vendors operating in this market. Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC. According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication. Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market. Key Vendors - Bayer - F. Hoffmann-La Roche - GlaxoSmithKline - Novartis - Pfizer Other Prominent Vendors - Abbott Laboratories - Active Biotech - Amgen - Argos Therapeutics - ArQule - AVEO Pharmaceuticals - Bionomics - Bristol-Myers Squibb - Cerulean Pharma - Exelixis - Genentech - immatics biotechnologies - Immunicum - Ono Pharmaceutical - Onyx Therapeutics - Oxford BioMedica - Prometheus Laboratories - Seattle Genetics - Taiwan Liposome - TRACON Pharmaceuticals - Wilex For more information visit http://www.researchandmarkets.com/research/s9...bal_kidney
ARGS: 6.19 (+0.14), ABT: 51.20 (+0.22), RXDX: 15.60 (-0.71), CERU: 4.24 (+0.04), AVEO: 1.61 (+0.01), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), TCON: 13.02 (-0.14), NVS: 103.05 (+1.75)
2015’s Top 6 Big Pharma Headlines Thus Far
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 7:16AM CDT
The pharmaceutical industry has certainly gotten off to another wild start in 2015. Despite the year being only half over at this point, we've already seen dozens of high profile mergers, several closely-watched experimental drugs report pivotal...
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), BMY: 68.24 (-1.13)
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates
at Investor's Business Daily - 53 mins ago
Large-cap drugmakers Valeant Pharmaceuticals, Eli Lilly and Bristol-Myers Squibb all beat analysts' Q2 estimates, but their stocks went in different directions, as their guidance was more mixed. Valeant (VRX) rose more than 6% after it said total...
VRX: 253.84 (+14.92), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Bristol-Myers Squibb Gets a Mixed Message From Investors
Brian Orelli, The Motley Fool - Motley Fool - 58 mins ago
Source: Bristol-Myers Squibb When a company beats revenue expectations by a wide margin, $4.2 billion actual versus a $3.7 billion consensus, as Bristol-Myers Squibb did, you'd expect shares to skyrocket. Instead the pharma is sitting down 1%...
GILD: 117.66 (+0.22), BMY: 68.24 (-1.13)
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 2:16PM CDT
Merck (MRK) announced that the European Commission has approved KEYTRUDA, for the treatment of advanced (unresectable or metastatic) melanoma in adults.
MRK: 58.07 (-0.06), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Shire Lifts 2015 Guidance On Strong Drug Pipeline
at Investor's Business Daily - Thu Jul 23, 1:42PM CDT
Shire (SHPG) missed analysts' targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker's adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on...
VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.78 (-0.10), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance
at Investor's Business Daily - Thu Jul 23, 9:58AM CDT
Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly's profit, excluding one-time items, rose...
LLY: 86.76 (+0.38), BMY: 68.24 (-1.13)
Surging new drug sales highlight strong Bristol-Myers Q2
By LINDA A. JOHNSON - AP - Thu Jul 23, 8:40AM CDT
Surging sales for new cancer, heart and hepatitis C medicines helped drugmaker Bristol-Myers Squibb Co. beat Wall Street expectations, and it boosted its 2015 profit forecast.
BMY: 68.24 (-1.13)
Valeant Earnings Soar On M&A, Organic Sales Growth
at Investor's Business Daily - Thu Jul 23, 8:37AM CDT
Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts' second-quarter revenue and earnings expectations. Valeant was one...
ENDP: 85.90 (-0.62), VRX: 253.84 (+14.92), SHPG: 261.24 (+1.78), RCPT: 228.27 (-0.13), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CELG: 139.01 (+0.75)
Stock Futures Up, But Volatile; SanDisk, Cirrus, Fortinet Soar
at Investor's Business Daily - Thu Jul 23, 8:17AM CDT
Stock futures were off to a neck-wrenching start Thursday, as earnings reports powered a volatile premarket session. Dow futures were up and down, showing a 4-point gain vs. fair market value 45 minutes before the start of regular trade. S&P 500...
AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), AXP: 77.01 (-1.98), RTN: 103.21 (+6.22), BMY: 68.24 (-1.13), QCOM: 61.78 (-2.41), PHM: 20.18 (+0.02), CRUS: 35.72 (+5.01), GM: 31.50 (+1.20), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), SNDK: 63.70 (+9.52)
Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:48AM CDT
Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View
BMY: 68.24 (-1.13)
Bristol-Myers Squibb Reports Second Quarter Financial Results
Business Wire - Thu Jul 23, 6:30AM CDT
--Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53
BMY: 68.24 (-1.13)
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe
Business Wire - Thu Jul 23, 5:30AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated two of the company's type II variation applications, which seek to extend the current indication for its Immuno-Oncology agent, Opdivo. Validation of the applications confirms that the submissions are complete and starts the EMA's centralized review process.
BMY: 68.24 (-1.13)
Presenting NPS2: Satmetrix to Introduce Next-Gen Net Promoter(R) Methodology at the 2015 International Net Promoter Conference in London, September 10 - 11
Marketwired - Thu Jul 23, 2:01AM CDT
Satmetrix(R), the leading global provider of cloud-based solutions for managing and improving customer experience, is returning to London for its 9th annual International Net Promoter Conference on September 10 - 11, 2015 at Chelsea Football Club's prestigious ground.
BMY: 68.24 (-1.13)
Market Wrap: Down Day Across the Board
at The Street - Wed Jul 22, 3:41PM CDT
Tech, telecom stocks lead major averages lower.
MMM: 149.50 (-5.91), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), CZR: 5.14 (+0.38), GM: 31.50 (+1.20), CRUS: 35.72 (+5.01), MCD: 97.09 (-0.49), CAT: 76.88 (-2.88), FTNT: 46.83 (+4.53), CMCSA: 62.47 (-2.03), DOW: 47.76 (-2.24), SNDK: 63.70 (+9.52), XOMA: 1.04 (+0.04)
Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:30PM CDT
Bristol-Myers (BMY) announced that the FDA has granted Breakthrough Therapy Designation to HIV candidate, BMS-663068.
SNSS: 3.47 (-0.05), LGND: 104.65 (-1.65), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4277fl/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Treatment (GBM) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. Based on drugs, the global glioblastoma treatment market has been segmented into Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU). The market for these drugs has been extensively analyzed based on consistency, effectiveness, and sales revenue of the drugs developed by the manufacturers. The market size and forecast in terms of USD million for each drug has been provided for the period from 2012 to 2022. Based on pipeline review, the global glioblastoma treatment market has been segmented into late stage (phase III) and early stage (Phase I&II). Drugs available in phase I and II are shown in a tabular format (significance, indication and intervention etc.). Likewise, the market size and forecast in terms of USD million for phase III candidate has been forecasted from 2014 to 2022. A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics. The pipeline review of glioblastoma treatment market has been segmented as below: Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs - Bevacizumab (Avastin) - Temozolomide (Temodar and Temodal and Temcad) - Carmustine (BiCNU) Global Pipeline Review of Glioblastoma Treatment - Overview - Late Stage (Phase III) - - DCVax - - Rindopepimut (CDX-110) - - Others - Early Stage (Phase I, II and Pre clinical) - - ABT-414 - - MM-398 - - ARC-100 - - AV0113 - - Cotara - - Crenolanib - - SGT-53 - - Endostatin - - ANG1005 - Others Companies Mentioned - AbbVie, Inc. - Activartis GmbH - Agenus Inc. - Arog Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.) - Cavion LLC - Celldex Therapeutics Inc. - Cortice Biosciences Inc. - Eisai Co., Ltd. - Exelixis Inc. - F. Hoffmann-La Roche Ltd. - Merrimack Pharmaceuticals, Inc. - OncoSynergy - Peregrine Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ioblastoma
MACK: 10.43 (unch), CLDX: 25.33 (-0.21), ABBV: 70.52 (-0.04), CTIC: 1.92 (+0.01), BMY: 68.24 (-1.13), EXEL: 5.88 (-0.43)
Global Kidney Cancer Drugs Market 2015-2019 with Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Pfizer Leading the Market
M2 - Wed Jul 22, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9gbg4/global_kidney) has announced the addition of the "Global Kidney Cancer Drugs Market 2015-2019" report to their offering. The global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019. The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer. The report also includes a discussion of the key vendors operating in this market. Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC. According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication. Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market. Key Vendors - Bayer - F. Hoffmann-La Roche - GlaxoSmithKline - Novartis - Pfizer Other Prominent Vendors - Abbott Laboratories - Active Biotech - Amgen - Argos Therapeutics - ArQule - AVEO Pharmaceuticals - Bionomics - Bristol-Myers Squibb - Cerulean Pharma - Exelixis - Genentech - immatics biotechnologies - Immunicum - Ono Pharmaceutical - Onyx Therapeutics - Oxford BioMedica - Prometheus Laboratories - Seattle Genetics - Taiwan Liposome - TRACON Pharmaceuticals - Wilex For more information visit http://www.researchandmarkets.com/research/s9...bal_kidney
ARGS: 6.19 (+0.14), ABT: 51.20 (+0.22), RXDX: 15.60 (-0.71), CERU: 4.24 (+0.04), AVEO: 1.61 (+0.01), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), TCON: 13.02 (-0.14), NVS: 103.05 (+1.75)
2015’s Top 6 Big Pharma Headlines Thus Far
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 7:16AM CDT
The pharmaceutical industry has certainly gotten off to another wild start in 2015. Despite the year being only half over at this point, we've already seen dozens of high profile mergers, several closely-watched experimental drugs report pivotal...
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), BMY: 68.24 (-1.13)
